Treatment with certolizumab pegol is beneficial for patients with axial spondyloarthritis in real-world clinical practice, suggest findings from the CIMAX study.
Preliminary findings from the GRECCO-19 trial suggest that colchicine, an anti-inflammatory drug used in the treatment of gout and familial Mediterranean fever, may have potential as a therapeutic agent for COVID-19.
Patients with rheumatic diseases, particularly fibromyalgia, have elevated rates of self-harm, according to data from the Clinical Practice Research Datalink.
The likelihood of experiencing an adverse event after initiating treatment with a first biologic DMARD increases with age and is higher in women than men, show data from a real-world study among people with rheumatic diseases.
Home confinement during the COVID-19 pandemic is associated with a reduction in medication intake and a worsening of disease activity among patients with spondyloarthritis, survey results suggest.
Add-on treatment with the IL-6 inhibitor tocilizumab may improve outcomes for patients with severe COVID-19, suggest findings from two retrospective cohort studies.
Diacerein has comparable efficacy to celecoxib for pain reduction in patients with moderate-to-severe symptomatic knee osteoarthritis and is well tolerated, suggest study findings reported in Rheumatology.
Rheumatic diseases and their treatments may not be associated with outcomes of SARS-CoV-2 infection, but older age and comorbidities are likely risk factors for a severe COVID-19 disease course in rheumatology patients, suggest findings from two studies.
Romosozumab and other sclerostin inhibitors may increase cardiovascular risk, suggests evidence from a meta-analysis of randomized trials and a study of genetic variants that mimic pharmacologic inhibition of sclerostin.
Both underweight and obese people with rheumatoid arthritis are at increased risk for discontinuing TNF inhibitor treatment earlier than their normal weight counterparts, real-world study findings indicate.
The outcomes of patients with rheumatoid arthritis could be improved by using the biologic DMARD option most appropriate to the age group, say Japanese researchers who assessed retention rates by age.
Preliminary findings from the Spanish BIOBADASER registry suggest that patients with rheumatic and musculoskeletal diseases may not have an elevated risk for COVID-19 hospitalization or mortality compared with the general population.
The American College of Rheumatology has issued two draft clinical guidance documents for the management of pediatric patients during the COVID-19 pandemic.
Sarilumab treatment provides consistent benefits for a broad range of patients with rheumatoid arthritis (RA), suggests a subgroup analysis of data from phase 3 trials.
Preliminary data suggest that the interleukin-1β inhibitor canakinumab may warrant further investigation as a treatment option for patients with COVID-19 who experience a hyper-inflammatory response.